Welcome to our dedicated page for Enanta Pharmaceuticals news (Ticker: ENTA), a resource for investors and traders seeking the latest updates and insights on Enanta Pharmaceuticals stock.
Enanta Pharmaceuticals, Inc. (ENTA) is a biotechnology leader focused on discovering novel small molecule drugs for viral infections and liver diseases. This dedicated news hub provides investors and industry observers with essential updates on the company's research advancements, regulatory milestones, and strategic initiatives.
Access authoritative coverage of ENTA's progress in developing direct-acting antiviral therapies and host-targeted approaches. The repository includes press releases related to clinical trial outcomes, partnership announcements with pharmaceutical collaborators, and updates on pipeline candidates targeting conditions like RSV and NASH.
Key updates feature developments in ENTA's chemistry-driven drug discovery platform, intellectual property achievements, and financial performance reports. All content is curated to support informed analysis of the company's position in the competitive antiviral therapeutics market.
Bookmark this page for streamlined access to verified ENTA developments. Check regularly for updates on FDA interactions, scientific publications, and partnership-driven commercialization efforts that shape the company's growth strategy.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) announced key developments for 2022 during the J.P. Morgan Healthcare Conference on January 11. The company plans to initiate a Phase 1 study of EDP-235, a COVID-19 treatment, in February 2022. Additionally, enrollment is complete for the Phase 2 RSVP study of EDP-938 for RSV, with data expected in Q2 2022. Enanta also introduced EDP-323, a new RSV candidate, aiming for a Phase 1 study in H2 2022. The company remains focused on advancing its virology pipeline and addressing urgent healthcare needs amid ongoing challenges from emerging COVID-19 variants.
Enanta Pharmaceuticals (NASDAQ:ENTA) announced that CEO Jay R. Luly, Ph.D., will present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 3:00 p.m. ET. A live webcast will be available on Enanta's website under the 'Events and Presentations' section, with a replay accessible for 30 days post-event.
Enanta focuses on developing small molecule drugs for viral infections and liver diseases, including clinical candidates for RSV, HBV, and COVID-19. Their R&D is funded by royalties from HCV products developed with AbbVie, including the notable drug MAVYRET®.
Enanta Pharmaceuticals has presented first preclinical data for EDP-235, an oral protease inhibitor targeting COVID-19, and reported positive Phase 1b results for EDP-514 in chronic HBV patients. The company terminated the development of EDP-721 due to safety concerns. For the fiscal year ended September 30, 2021, total revenue was $97.1 million, down from $122.5 million in 2020, primarily from unchanged royalty revenue of $23.6 million. Enanta recorded a net loss of $79.0 million for the year. The company expects sufficient cash to meet operational needs for at least two years.
Enanta Pharmaceuticals (NASDAQ:ENTA) announced participation in two virtual investor conferences in December 2021. Jay R. Luly, President and CEO, will speak at the Evercore ISI HealthCONx Conference on December 1, 2021, at 10:30 a.m. ET, and will also present at the Piper Sandler Healthcare Conference on December 2, 2021. A pre-recorded chat will be available to attendees on November 29, 2021. Webcasts will be accessible on Enanta's website and archived for 14 days.
Enanta Pharmaceuticals (NASDAQ:ENTA) announced the discontinuation of EDP-721, an oral HBV RNA destabilizer, due to safety concerns raised in a Phase 1 study. Despite a promising preclinical safety profile, emerging safety signals prompted the decision to prioritize patient safety. The company remains focused on EDP-514, a core inhibitor for HBV, which has shown robust antiviral activity in earlier trials. Enanta aims to develop a functional cure for chronic hepatitis B, leveraging its drug discovery capabilities and ongoing research efforts.
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) will release its fiscal fourth-quarter and full-year financial results on November 22, 2021, after market close. A conference call is scheduled for 4:30 p.m. ET to discuss the results and updates on their R&D pipeline, which includes candidates for RSV, HBV, and COVID-19. The company continues to fund its R&D through royalties from its collaboration with AbbVie on HCV products, specifically the protease inhibitor Glecaprevir.
Enanta Pharmaceuticals announces positive results from the final Phase 1b data of EDP-514, a new hepatitis B virus core inhibitor. At 800 mg, EDP-514 was shown to be safe and well-tolerated over 28 days, with robust antiviral activity reflected in a 3.5 log decline in HBV DNA in viremic patients. EDP-514's pharmacokinetics support once-daily oral dosing, paving the way for combination therapy strategies. The data was presented at The Liver Meeting® 2021, showcasing the potential of EDP-514 for chronic HBV treatment.
Enanta Pharmaceuticals (NASDAQ:ENTA) has released preclinical data for EDP-235, an oral protease inhibitor targeting COVID-19. The data, presented at the ISIRV-WHO Virtual Conference, shows EDP-235's potent inhibition of SARS-CoV-2, with an IC50 of 5.8 nM and effective action against variants. The drug demonstrated promising pharmacokinetic properties, including 95% oral bioavailability and a projected half-life of 16 hours, indicating potential for once-daily dosing. Enanta plans to advance EDP-235 into clinical studies in early 2022.
Enanta Pharmaceuticals (NASDAQ:ENTA) announced that new preclinical data for EDP-235, its lead oral protease inhibitor for COVID-19, will be presented at the ISIRV-WHO Virtual Conference from October 19-21, 2021. The poster presentation titled “EDP-235, A Potential Oral, Once-Daily Antiviral Treatment and Preventative for COVID-19” will be showcased on October 19 at 8:00 a.m. CET, presented by Li-Juan Jiang, Ph.D. The company continues to focus on developing antiviral treatments, supported by royalties from its collaboration with AbbVie for hepatitis C virus products.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) announced that CEO Jay R. Luly, Ph.D., will participate in a fireside chat on October 13, 2021, at 3:30 p.m. ET during the H.C. Wainwright 2nd Annual Hepatitis B Virus Virtual Conference. A live webcast of the presentation can be accessed on Enanta’s website, with replays available for 30 days post-event. Enanta focuses on small molecule drug discovery for viral infections and liver diseases, including candidates for respiratory syncytial virus, hepatitis B virus, and COVID-19.
